A preliminary study on the safety and effectiveness of the Unani compound drug Habb-e-Hindi-Zeeqi in cases of bronchial asthma (Zeeq-un-Nafas)

Effect of Habb-e-Hindi-Zeeqi in bronchial asthma patients.

Abstract

According to the 2019 Global Burden of Disease report, 34.3 million people in India suffer from asthma, making up 13.09% of the worldwide burden. A proper solution to this problem is still elusive in modern medicine. As a result, the world is anticipating certain traditional treatments in this area. For bronchial asthma, Unani doctors administer both single medications and several Unani formulations. One such frequently recommended Unani medicine is Habb-e-Hindi-Zeeqi. In the current study, the Regional Research Institute of Unani Medicine (RRIUM), Aligarh, conducted a clinical, biochemical, and haematological evaluation of the therapeutic efficacy and safety of the Unani compound medicine Habb-e-Hindi-Zeeqi during the years 2021-2022. Out of the patients who visited the outpatient department (OPD), a total of 26 patients were chosen. For four weeks, the patients received one tablet (125 mg) of the Unani compound medicine Habb-e-Hindi-Zeeqi orally twice a day after meals. The results were statistically assessed using Dennett's test one-way analysis of variance (ANOVA). According to the current study, the Unani compound medicine is safe, non-toxic, and highly successful in treating bronchial asthma. More research in a large population is advised.